← Leaderboards
David E Kang
Louis Stokes Cleveland Va Medical Center
$11,251,652
Attributed
$14,045,120
Total exposure
17
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,045,120 · 12
VA$0 · 5
By mechanism
R01$8,799,052 · 6
RF1$3,653,970 · 2
R21$1,251,107 · 3
K02$340,991 · 1
I01$0 · 5
Top collaborators
- Junga "Alexa" Woo8 shared
- Yu Chen2 shared
- Martin Muschol2 shared
- Stanley M Stevens2 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposProteinsBrainTau ProteinsCellsS DiseaseBiochemicalIn VivoPathway InteractionsNeuronsMolecularMediatingBiologicalPathogenesisSynapsesComplexTransgenic MiceInsightLinkPathologyTauopathiesMouse ModelMutantImpairment
Grant awards (54)
Deubiquitinase USP19 in TDP-43 pathogenesis.$595,610
R01 · FY2025 · NS · contact PI
SSH1-Nrf2 nexus in tipping the balance between degeneration and protection in tauopathies.$501,894
R01 · FY2025 · AG · contact PI
Pathological Signatures of CHCHD10 Dysfunction in ADRDs$402,500
R01 · FY2025 · NS · contact PI
Pathological signatures and pathways of CHCHD2 dysfunction in Lewy body diseases$0
I01 · FY2025 · VA · contact PI
SSH1-Nrf2 nexus in tipping the balance between degeneration and protection in tauopathies.$512,136
R01 · FY2024 · AG · contact PI
Deubiquitinase USP11 in tau regulation and age-related tauopathy$402,500
R01 · FY2024 · AG · contact PI
Pathological signatures of CHCHD10 dysfunction in ADRDs$390,425
R01 · FY2024 · NS · contact PI
Fluorescent probes for detection of misfolded protein oligomers in Alzheimer's Disease and related disorders$228,457
R21 · FY2024 · AG
Divergent roles of Slingshot-1 in tauopathy$0
I01 · FY2024 · VA · contact PI
SSH1-Nrf2 nexus in tipping the balance between degeneration and protection in tauopathies.$505,696
R01 · FY2023 · AG · contact PI
Deubiquitinase USP11 in tau regulation and age-related tauopathy$402,500
R01 · FY2023 · AG · contact PI
Pathological signatures of CHCHD10 dysfunction in ADRDs$402,500
R01 · FY2023 · NS · contact PI
Fluorescent probes for detection of misfolded protein oligomers in Alzheimer's Disease and related disorders$200,400
R21 · FY2023 · AG
Divergent roles of Slingshot-1 in tauopathy$0
I01 · FY2023 · VA · contact PI
Deubiquitinase USP19 in TDP-43 pathogenesis.$1,785,220
RF1 · FY2022 · NS · contact PI
Pathological signatures of CHCHD10 dysfunction in ADRDs$402,500
R01 · FY2022 · NS · contact PI
Deubiquitinase USP11 in tau regulation and age-related tauopathy$402,500
R01 · FY2022 · AG · contact PI
Divergent roles of Slingshot-1 in tauopathy$0
I01 · FY2022 · VA · contact PI
Pathological signatures of CHCHD10 dysfunction in ADRDs$402,500
R01 · FY2021 · NS · contact PI
Deubiquitinase USP11 in tau regulation and age-related tauopathy$341,530
R01 · FY2021 · AG · contact PI
Deubiquitinase USP11 in tau regulation and age-related tauopathy$32,220
R01 · FY2021 · AG · contact PI
Divergent roles of Slingshot-1 in tauopathy$0
I01 · FY2021 · VA · contact PI
Divergent roles of Slingshot-1 in tauopathy$0
I01 · FY2021 · VA · contact PI
Deubiquitinase USP11 in tau regulation and age-related tauopathy$373,750
R01 · FY2020 · AG · contact PI
Targeting Tau for TBI$0
I01 · FY2020 · VA · contact PI
The hsp90 Cochaperone FKBP51 Regulates tau Structure and Function$483,054
R01 · FY2019 · NS · contact PI
UPR as a Neuronal Death Mediator in Alzheimer's Disease$0
I01 · FY2019 · VA · contact PI
Targeting Tau for TBI$0
I01 · FY2019 · VA · contact PI
Molecular Intermediates and Regulation of the Abeta-Tau Pathogenic Cascade$0
I01 · FY2019 · VA · contact PI
The hsp90 Cochaperone FKBP51 Regulates tau Structure and Function$510,961
R01 · FY2018 · NS · contact PI
UPR as a Neuronal Death Mediator in Alzheimer's Disease$0
I01 · FY2018 · VA · contact PI
Targeting Tau for TBI$0
I01 · FY2018 · VA · contact PI
Molecular Intermediates and Regulation of the Abeta-Tau Pathogenic Cascade$0
I01 · FY2018 · VA · contact PI
Role of the Slingshot-1 pathway in APP and Tau pathogenesis$1,215,090
RF1 · FY2017 · AG · contact PI
Role of the Slingshot-1 pathway in APP and Tau pathogenesis$653,660
RF1 · FY2017 · AG · contact PI
The hsp90 Cochaperone FKBP51 Regulates tau Structure and Function$510,962
R01 · FY2017 · NS · contact PI
Directional proteome analysis of extracellular vesicles in AD models$186,875
R21 · FY2017 · AG · contact PI
Targeting Tau for TBI$0
I01 · FY2017 · VA · contact PI
Molecular Intermediates and Regulation of the Abeta-Tau Pathogenic Cascade$0
I01 · FY2017 · VA · contact PI
UPR as a Neuronal Death Mediator in Alzheimer's Disease$0
I01 · FY2017 · VA · contact PI
Directional proteome analysis of extracellular vesicles in AD models$224,250
R21 · FY2016 · AG · contact PI
Structure-based Identification and Functional Characterization of SSH1 Inhibitors$186,875
R21 · FY2016 · AG · contact PI
Molecular Intermediates and Regulation of the Abeta-Tau Pathogenic Cascade$0
I01 · FY2016 · VA · contact PI
Structure-based Identification and Functional Characterization of SSH1 Inhibitors$224,250
R21 · FY2015 · AG · contact PI
Molecular Intermediates and Regulation of the Abeta-Tau Pathogenic Cascade$0
I01 · FY2015 · VA · contact PI
Novel Mechanisms of RanBP9 in APP Pathogenesis$291,639
R01 · FY2012 · AG · contact PI
Novel Mechanisms of RanBP9 in APP Pathogenesis$201,703
R01 · FY2011 · AG · contact PI
Novel Mechanisms of RanBP9 in APP Pathogenesis$99,689
R01 · FY2011 · AG · contact PI
LRP/RanBP9 Pathway in Alzheiimer's Disease Pathogenesis$61,517
K02 · FY2011 · AG · contact PI
LRP/RanBP9 Pathway in Alzheiimer's Disease Pathogenesis$55,279
K02 · FY2011 · AG · contact PI
Novel Mechanisms of RanBP9 in APP Pathogenesis$313,558
R01 · FY2010 · AG · contact PI
LRP/RanBP9 Pathway in Alzheiimer's Disease Pathogenesis$113,597
K02 · FY2010 · AG · contact PI
Novel Mechanisms of RanBP9 in APP Pathogenesis$316,725
R01 · FY2009 · AG · contact PI
LRP/RanBP9 Pathway in Alzheiimer's Disease Pathogenesis$110,598
K02 · FY2009 · AG · contact PI